Related Experiment Videos
Replicating viruses as selective cancer therapeutics
1Director of Pre-clinical and Clinical Research, ONYX Pharmaceuticals, Richmond, CA 94806, USA.
Abstract:
Replication-competent viruses are used as selective cancer therapeutics and the mechanisms leading to tumor-specific replication and antitumoral efficacy are now becoming apparent. The specific viruses in development include tumor-targeting herpes simplex viruses, autonomous parvoviruses, Newcastle disease viruses and adenovirus. Information is also available on antiviral immunology and viral defenses against host-mediated immunity. This approach has many potential attributes, in addition to potential hurdles that must be overcome.
Insights
Replication-competent viruses show promise as cancer therapies, with research clarifying tumor-specific replication and effectiveness. Various viruses are under development, alongside studies on antiviral immunology and overcoming immune defenses.
Area of Science:
- Oncolytic virotherapy
- Cancer immunology
Background:
- Replication-competent viruses are emerging as targeted cancer therapeutics.
- Understanding tumor-specific viral replication and efficacy is crucial.
Purpose of the Study:
- To review the mechanisms of tumor-specific viral replication and antitumoral efficacy.
- To highlight viruses currently in development for cancer therapy.
- To discuss antiviral immunology and host defenses in this context.
Main Methods:
- Review of current literature on oncolytic viruses.
- Analysis of viral mechanisms for tumor targeting and replication.
- Examination of immunological responses to viral cancer therapy.
Main Results:
- Mechanisms for tumor-specific viral replication and efficacy are becoming clearer.
- Several virus types are in development, including herpes simplex viruses, parvoviruses, Newcastle disease viruses, and adenoviruses.
- Insights into antiviral immunology and host immune evasion strategies are available.
Conclusions:
- Oncolytic virotherapy holds significant therapeutic potential for cancer treatment.
- Further research is needed to overcome existing hurdles for clinical application.